Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Treatment of Patients With RAD001 With Progressive Sarcoma
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT00767819
- Locations
- 🇮🇹
Novartis Investigative Site, Milano, MI, Italy
Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 40
- Registration Number
- NCT00762632
- Locations
- 🇩🇪
Medical faculty of the Technical University Munich, Munich, Bavaria, Germany
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT00756340
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
- Conditions
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 35
- Registration Number
- NCT00727207
- Locations
- 🇩🇪
Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
- Conditions
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 120
- Registration Number
- NCT00716573
- Locations
- 🇫🇷
Hospices Civils de Lyon, Lyon, France
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT00702052
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Hillman Cancer Center (4), Pittsburgh, Pennsylvania, United States
🇺🇸Bay Area Cancer Research Dept.ofBayAreaCancerResearch, Concord, California, United States
🇺🇸Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States
Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant
- Conditions
- Interventions
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Fundacion Investigacion y Desarrollo
- Target Recruit Count
- 52
- Registration Number
- NCT00695344
- Locations
- 🇪🇸
Hospital Gregorio Marañón, Madrid, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
🇪🇸Hospital de Bellvitge, Barcelona, Spain
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT00688623
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00680758
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Cancer Center at Centennial Medical Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 82
- Registration Number
- NCT00674414
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷Centre Oscar Lambret, Lille, France
🇫🇷Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.